Purpose: To determine if C-reactive protein (CRP) can predict the outcomes of lower extremity endovascular therapy (EVT) in patients with peripheral artery disease and to calculate a cutoff value that may be useful in identifying patients with a higher risk of EVT failure at 1 year. Methods: In this prospective single-center study, 121 patients (94 men; mean age 67.7±9.8 years) undergoing EVT of lower limb lesions in an 18-month period were enrolled as a derivation set. In the subsequent 6 months, 53 patients (39 men; mean age 70.1±10.0 years) were enrolled as the validation set. Blood samples were collected before EVT and at 1 month postintervention from both sets of patients to measure CRP levels. The cohorts were followed for 1 year, and data on reinterventions were recorded. A cutoff CRP value was calculated with the highest sensitivity and specificity for EVT failure based on receiver operator characteristic (ROC) curve analysis. The cutoff value was confirmed in the validation set. Cox proportional hazards analysis was performed to evaluate the independent contribution of CRP levels and other variables to the risk of reintervention; results are given as the hazard ratio (HR) and 95% confidence interval (CI). Results: The area under the ROC curve relating preprocedure CRP levels to 1-year reintervention was 0.77±0.05. The highest likelihood ratio corresponded to a pre-EVT CRP value of 9.8 mg/L (likelihood ratio test=133, df=1, p<0.001). Reintervention before the first year after EVT was related to preprocedure CRP levels (HR 1.1, 95% CI 1.05 to 1.2; p<0.001). These results were confirmed in the validation set (HR 1.1, 95% CI 1.02 to 1.18; p=0.008). Conclusion: CRP values can be used as an independent marker of EVT outcome. Baseline CRP levels >9.8 mg/L indicate increased risk of secondary interventions, which are often open surgical procedures.
RidkerPMCushmanMStampferMJ. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425–428.
2.
TzoulakiIMurrayGDLeeAJ. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 2005;112:976–983.
3.
De HaroJAcinFMedinaFJ. Relationship between the plasma concentration of C-reactive protein and severity of peripheral arterial disease. Clin Med Cardiol. 2008;3:1–7.
4.
RidkerPMStampferMJRifaiN. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481–2485.
5.
Van Der MeerIMDe MaatMPHakAE. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke. 2002;33:2750–2755.
6.
AboyansVCriquiMHDenenbergJO. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113:2623–2629.
7.
MusicantSETaylorLMPetersD. Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease. J Vasc Surg. 2006;43:772–780.
8.
BradburyAWAdamDJBellJ; BASIL trial Participants. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. J Vasc Surg. 2010;51(5 suppl):18S–31S.
9.
BledaSDe HaroJAcinF. Inflammatory burden predicts long-term outcomes in endovascular therapy in peripheral arterial disease. Ann Vasc Surg. 2013;27:459–466.
10.
SchillingerMExnerMMlekuschW. Endovascular revascularization below the knee: 6-month results and predictive value of C-reactive protein level. Radiology. 2003;227:419–425.
11.
IshiiHAoyamaTTakahashiH. Serum albumin and C-reactive protein levels predict clinical outcome in hemodialysis patients undergoing endovascular therapy for peripheral artery disease. Atherosclerosis. 2013;227:130–134.
12.
NorgrenLHiattWRDormandyJA; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
13.
FeigelsonHSCriquiMHFronekA. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. Am J Epidemiol. 1994;140:526–534.
14.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2001;24:5–20.
15.
VerdecchiaPAngeliF. The seventh report of the joint national committee on the prevention, detection, evaluation and treatment of high blood pressure: the weapons are ready. Rev Esp Cardiol. 2003;56:843–847.
16.
National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III, or ATP III). http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.htm. Accessed January 7, 2015.
RankeCCreutzigAAlexanderK. Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 1992;18:433–440.
19.
EdaSKaufmannJRoosW. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal. 1998;12:137–144.
20.
SchillingerMHaumerMSchlerkaG. Restenosis after percutaneous transluminal angioplasty in patients with peripheral artery disease: the role of inflammation. J Endovasc Ther. 2001;8:477–483.
21.
BeregiJPLehalleBCardonJM. Stenting in superficial femoral artery and usCRP: multicentric study SAFE in 255 patients. Presse Med. 2010;39:265–272.
22.
StonePASchlarbHCampbellJE. C-reactive protein and brain natriuretic peptide as predictors of adverse events after lower extremity endovascular revascularization. J Vasc Surg. 2014;60:652–660.
23.
ChoiDHParkKWYangHM. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. Int J Cardiol. 2011;149:174–181.
24.
DelhayeCSudreALemesleG. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. Cardiovasc Revasc Med. 2009;10:144–150.
25.
Biondi-ZoccaiGAbbateALiuzzoG. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol. 2003;41:1071–1077.
26.
CermakJKeyNSBachRR. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513–520.
